Trial reportBritish journal of clinical pharmacology2017
The effect of co-trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial.
Trial report in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- The effect of co-trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial.British journal of clinical pharmacology · 2017Trial
- [Changes in renal function parameters after cotrimoxazole therapy].Innere Medizin (Heidelberg, Germany) · 2025Article
- Hyperkalemic effect of drug-drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study.Journal of pharmaceutical health care and sciences · 2024Article
- Incidence of Co-Trimoxazole-Induced Hyperkalemia in a Tertiary Care Hospital.Risk management and healthcare policy · 2021Article
- Co-trimoxazole induced hyperkalemia and potassium monitoring in hospitalized patients.International journal of clinical pharmacy · 2020Article
- Co-trimoxazole induced hyperkalemia and potassium monitoring in hospitalized patients.International journal of clinical pharmacy · 2020Article
- Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study.BMJ (Clinical research ed.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
aimsCo-trimoxazole maintains a well-established role in the treatment of Pneumocystis jirovecii and Toxoplasma gondii, as well as urinary tract infections. Observational studies report hyperkalaemia to be associated with co-trimoxazole, which may stem from an amiloride-like potassium-sparing effect. The current study investigated changes in serum potassium in patients without acute infections, and the influence of concomitant antikaliuretic drugs on this effect.
methodsA post hoc analysis was carried out of a randomized controlled trial in patients with interstitial lung disease who were assigned to placebo or 960 mg co-trimoxazole twice daily. Serum potassium and creatinine were measured at baseline, 6 weeks, and 6, 9 and 12 months. The primary outcome was the difference in mean serum potassium concentrations between co-trimoxazole and placebo at 6 weeks.
resultsMean serum potassium levels were similar at baseline: 4.24 (± 0.44) mmol l
conclusionsCo-trimoxazole significantly increases serum potassium concentration, even in participants not using antikaliuretic drugs. While the magnitude of increase was often minor, a small proportion in our outpatient cohort developed hyperkalaemia of clinical importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.